COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation

Oncotarget. 2017 Feb 7;8(6):10185-10198. doi: 10.18632/oncotarget.14363.

Abstract

Hyperuricemia is not only the main feature of gout but also a cause of gout-related organ injuries including glomerular hypertrophy and sclerosis. Uric acid (UA) has been proven to directly cause mesangial cell (MC) proliferation with elusive mechanisms. The present study was undertaken to examined the role of inflammatory cascade of COX-2/mPGES-1/PGE2 in UA-induced MC proliferation. In the dose- and time-dependent experiments, UA increased cell proliferation shown by the increased total cell number, DNA synthesis rate, and the number of cells in S and G2 phases in parallel with the upregulation of cyclin A2 and cyclin D1. Interestingly, UA-induced cell proliferation was accompanied with the upregulation of COX-2 and mPGES-1 at both mRNA and protein levels. Strikingly, inhibition of COX-2 via a specific COX-2 inhibitor NS-398 markedly blocked UA-induced MC proliferation. Meanwhile, UA-induced PGE2 production was almost entirely abolished. Furthermore, inhibiting mPGES-1 by a siRNA approach in MCs also ameliorated UA-induced MC proliferation in line with a significant blockade of PGE2 secretion. More importantly, in gout patients, we observed a significant elevation of urinary PGE2 excretion compared with healthy controls, indicating a translational potential of this study to the clinic. In conclusion, our findings indicated that COX-2/mPGES-1/PGE2 cascade activation mediated UA-induced MC proliferation. This study offered new insights into the understanding and the intervention of UA-related glomerular injury.

Keywords: COX-2; PGE2; mPGES-1; mesangial cells; uric acid.

MeSH terms

  • Aged
  • Animals
  • Case-Control Studies
  • Cell Line
  • Cell Proliferation / drug effects*
  • Cyclin A2 / metabolism
  • Cyclin D1 / metabolism
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism*
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Dinoprostone / metabolism*
  • Dinoprostone / urine
  • Dose-Response Relationship, Drug
  • Female
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Gout / enzymology*
  • Gout / genetics
  • Gout / pathology
  • Gout / urine
  • Humans
  • Hyperuricemia / enzymology*
  • Hyperuricemia / genetics
  • Hyperuricemia / pathology
  • Hyperuricemia / urine
  • Male
  • Mesangial Cells / drug effects*
  • Mesangial Cells / enzymology
  • Mesangial Cells / pathology
  • Mice
  • Middle Aged
  • Prostaglandin-E Synthases / genetics
  • Prostaglandin-E Synthases / metabolism*
  • RNA Interference
  • S Phase Cell Cycle Checkpoints / drug effects
  • Signal Transduction / drug effects
  • Time Factors
  • Transfection
  • Uric Acid / pharmacology*

Substances

  • CCNA2 protein, mouse
  • Ccnd1 protein, mouse
  • Cyclin A2
  • Cyclooxygenase 2 Inhibitors
  • Cyclin D1
  • Uric Acid
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Prostaglandin-E Synthases
  • Ptges protein, mouse
  • Dinoprostone